Middle School Teacher Methods for Cultivating Student Autonomy: A PLC Case Study During COVID-19

The purpose of this PLC-informed qualitative interview case study was to explore middle school teacher methods for cultivating student autonomy and the rationale behind their instructional choices. Here, student autonomy was defined as learners taking ownership of their academic performance and scholastic responsibilities (Holec, 1981). The unforeseen emergence of COVID-19 impacted the format of this study and provided a rare opportunity for a six-week, nine-member professional learning community (PLC) focusing on the topic of student autonomy. A survey questionnaire, PLC transcripts, and 30-minute semi-structured qualitative exit interviews underwent thematic coding analysis to place teacher responses in the context of predominant voices found in academia today. Themes are examined from a leadership perspective, through the social justice lens of critical pedagogy (Freire, 1970; Giroux, 2011; McLaren, 2015). This study evolved to capture the teachers\u27 lived experiences during the pandemic in order to gain their perspectives on how autonomy shifted along with the traditional means of instruction during this time of seismic change. Discussed are themes of performativity, teacher authenticity, social and emotional learning (SEL), PLCs as professional development (PD), motivation, constructivism, adaptive expertise, and metacognition, along with several others, nesting teachers\u27 practical experience in the rich context of pedagogical theory, specifically when navigating new roles in remote and hybrid instruction

sk_p: a neural program corrector for MOOCs

We present a novel technique for automatic program correction in MOOCs, capable of fixing both syntactic and semantic errors without manual, problem specific correction strategies. Given an incorrect student program, it generates candidate programs from a distribution of likely corrections, and checks each candidate for correctness against a test suite. The key observation is that in MOOCs many programs share similar code fragments, and the seq2seq neural network model, used in the natural-language processing task of machine translation, can be modified and trained to recover these fragments. Experiment shows our scheme can correct 29% of all incorrect submissions and out-performs state of the art approach which requires manual, problem specific correction strategies

Proglucagon-derived peptides as therapeutics

Initially discovered as an impurity in insulin preparations, our understanding of the hyperglycaemic hormone glucagon has evolved markedly over subsequent decades. With description of the precursor proglucagon, we now appreciate that glucagon was just the first proglucagon-derived peptide (PGDP) to be characterised. Other bioactive members of the PGDP family include glucagon-like peptides -1 and -2 (GLP-1 and GLP-2), oxyntomodulin (OXM), glicentin and glicentin-related pancreatic peptide (GRPP), with these being produced via tissue-specific processing of proglucagon by the prohormone convertase (PC) enzymes, PC1/3 and PC2. PGDP peptides exert unique physiological effects that influence metabolism and energy regulation, which has witnessed several of them exploited in the form of long-acting, enzymatically resistant analogues for treatment of various pathologies. As such, intramuscular glucagon is well established in rescue of hypoglycaemia, while GLP-2 analogues are indicated in the management of short bowel syndrome. Furthermore, since approval of the first GLP-1 mimetic for the management of Type 2 diabetes mellitus (T2DM) in 2005, GLP-1 therapeutics have become a mainstay of T2DM management due to multifaceted and sustainable improvements in glycaemia, appetite control and weight loss. More recently, longer-acting PGDP therapeutics have been developed, while newfound benefits on cardioprotection, bone health, renal and liver function and cognition have been uncovered. In the present article, we discuss the physiology of PGDP peptides and their therapeutic applications, with a focus on successful design of analogues including dual and triple PGDP receptor agonists currently in clinical development

Sustained glucagon receptor antagonism in insulin deficient high fat fed mice

Discerning modification to the amino acid sequence of native glucagon can generate specific glucagon receptor (GCGR) antagonists, that include desHis(1)Pro(4)Glu(9)-glucagon and the acylated form desHis(1)Pro(4)Glu(9)(Lys(12)PAL)-glucagon. In the current study, we have evaluated the metabolic benefits of once-daily injection of these peptide-based GCGR antagonists for 18 days in insulin-resistant high-fat-fed (HFF) mice with streptozotocin (STZ)-induced insulin deficiency, namely HFF-STZ mice. Administration of desHis(1)Pro(4)Glu(9)-glucagon moderately (P < 0.05) decreased STZ-induced elevations of food intake. Body weight was not different between groups of HFF-STZ mice and both treatment interventions delayed (P < 0.05) the onset of hyperglycaemia. The treatments reduced (P < 0.05–P < 0.001) circulating and pancreatic glucagon, whilst desHis(1)Pro(4)Glu(9)(Lys(12)PAL)-glucagon also substantially increased (P < 0.001) pancreatic insulin stores. Oral glucose tolerance was appreciably improved (P < 0.05) by both antagonists, despite the lack of augmentation of glucose-stimulated insulin release. Interestingly, positive effects on i.p. glucose tolerance were less obvious suggesting important beneficial effects on gut function. Metabolic benefits were accompanied by decreased (P < 0.05–P < 0.01) locomotor activity and increases (P < 0.001) in energy expenditure and respiratory exchange ratio in both treatment groups. In addition, desHis(1)Pro(4)Glu(9)-glucagon increased (P < 0.01–P < 0.001) O(2) consumption and CO(2) production. Together, these data provide further evidence that peptidic GCGR antagonists are effective treatment options for obesity-driven forms of diabetes, even when accompanied by insulin deficiency

Metabolic effects of combined glucagon receptor antagonism and glucagon-like peptide-1 receptor agonism in high fat fed mice

Acknowledgements This work was supported by an Invest Northern Ireland Proof- of-Concept grant, a Department for the Economy, Northern Ireland PhD studentship and Ulster University Selective Research Funding.Peer reviewedPublisher PD

Sustained glucagon receptor antagonism in insulin deficient high fat fed mice

This work was supported by an Invest Northern Ireland Proof-of-Concept grant (PoC106), a Department for the Economy, Northern Ireland PhD studentship and Ulster University Selective Research FundingPeer reviewedPublisher PD